Our group studies the properties of oncoproteins that drive cancer cell growth, focusing on lung cancer and other solid tumors. We are interested in understanding how these are activated, their regulatory mechanisms, and how they modulate the behavior of cancer cells. To answer these questions we utilize small molecule inhibitors coupled with biochemical and genetic approaches in patient-derived cell line or xenograft model systems. We aim to provide insight into the fundamental processes that govern tumor biology and to identify therapeutic interventions that will prolong survival and improve the quality of life in patients with cancer.
- Lito, P*; Solomon, M; Li, L; Hansen, R and Rosen*, N; Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Science, 2016, 10.1126/science.aad6204. *Co-corresponding authors
- Lito, P; Saborowski, A; Yue J; Solomon, M; Joseph, E; Saborowski, M; Fellmann, C; Ohara, K; Morikami, K; Miura, T; Lukas, C; Ishii, N; Lowe, S and Rosen, N; Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Cancer Cell, 2014, 25(5):697-710.
- The V Foundation for Cancer Research, Translational Research Award (2015)
- LUNGevity Foundation, Career Development Award (2015)
- NIH K08, Mentored Clinical Scientist Research Career Development Award (2015)
- Stand up to Cancer Lung Cancer Dream Team, Young Investigator (2015)
- Conquer Cancer Foundation, Young Investigator Award (2013)
- Charles A. Dana Fellow/Clinical Scholar in Biomedical Research (2011)